The combination of FOLFOX-4 and Cetuximab has also been demonstrated to be effective with regard to response rate (57 to 81 %) and progression-free survival with good tolerance, in patients with non-mutated KRAS (wild-type) metastatic colorectal cancer [39–46]. Here, KRAS is linked to metastatic colorectal cancer.